Navigation Links
Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer
Date:11/8/2009

Freeze-drying of biopharmaceuticals to be available at the Company’s Mississauga, Ontario facility.

Toronto, ON (PRWEB) November 8, 2009 -- Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced that the Company has taken delivery of a commercial scale pharmaceutical grade freeze dryer and expects to make commercial scale freeze drying (lyophilization) available for contract manufacturing of biopharmaceuticals early in 2010.

Lyophilization is used to convert biopharmaceuticals that are manufactured in an unstable liquid format into a stable, dry powder that can be reconstituted to a liquid format for administration to patients. Lyophilized forms of these life-saving products are more easily handled and stable than their liquid forms and therefore lyophilization is commonly used in the manufacture of these products.

“Commercial scale lyophilization is not readily available in Canada,” said Thomas Wellner. “The addition of a commercial-scale lyophilizer to the clinical scale capability Therapure Biopharma has now will significantly enhance the value we will bring to Therapure clients.”

Installation of the lyophilizer began last week and is expected to be completed in December. Following the installation, the Company will complete the extensive validation process required to achieve current Good Manufacturing Practices (cGMP) status. Therapure Biopharma will begin offering commercial-scale lyophilization services from its Health Canada commercially licensed plant early in 2010.

About Therapure Biopharma:
Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies, and packages therapeutic proteins. As a contract development and manufacturing organization (CDMO) Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market.

For more information, please visit: www.therapurebio.com

Media Contacts:
Thomas Wellner, President and CEO
Therapure Biopharma Inc.
+1 905-286-6204

# # #

Read the full story at http://www.prweb.com/releases/2009/11/prweb3172054.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Therapure Biopharma Inc. and LFB Biotechnologies Announce Development Services Contract for New Therapeutic Protein
2. Surviving Healthcare Reform: How Biopharma Companies Can Come Out on Top
3. aTyr Pharma to Present at Japan Biopharma Partnering Conference
4. Keryx Biopharmaceuticals, Inc. to Hold Investor/Analyst Day Tomorrow
5. DOR BioPharma Announces $9.4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines
6. PDL BioPharma Announces Conversion Rate Adjustment for Its 2.75% Convertible Subordinated Notes Due August 16, 2023
7. Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma
8. UK's Newcastle University Introduces First-Ever Biopharmaceutical Engineering Doctorate Program
9. PDL BioPharma to Present at BioCentury Newsmakers Conference on September 16, 2009
10. Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma
11. Keryx Biopharmaceuticals, Inc. To Present at the Rodman & Renshaw Annual Global Investment Conference and To Hold Investor/Analyst Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... PA (PRWEB) , ... September 25, 2017 , ... PITTSBURGH...An ... way to update patient charts in hospitals and medical facilities, so he invented the ... access and update patient charts. In doing so, it offers an improved alternative to ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... supporting clinical research, today announces that 30 of its domain experts will ... development lifecycle at upcoming industry conferences and webinars. Drawing on broad and ...
(Date:9/25/2017)... Korea (PRWEB) , ... September 25, 2017 , ... Earlypicker ... looking for a one-stop shop for the hottest Korean cosmetics and fashion trends sweeping ... for a company that’s already well-known for the great offerings that allow Koreans everywhere ...
(Date:9/25/2017)... ... , ... “The Majestic Unicorn”: a poignant book that describes what happened ... creation of published author, Dayna Chantel, an artist and a writer. , Chantel shares, ... aboard the cypress ark-vessel. Male and female, no matter what species, they were chosen ...
(Date:9/25/2017)... ... ... Emerald Ash Borers kill Ash trees in as little as 1-3 years. The ... video by Rob Nagy, ISA Certified Arborist at Giroud Tree and Lawn, shows a street ... showing signs of decline from Emerald Ash Borers, two Ash trees continue to thrive. ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... SAN ANTONIO , Sept. 6, 2017  Robert ... as a Pinnacle Professional Member in recognition of his ... Dr. Szewc serves as a Nephrologist at the practice ... services, emergency medicine, kidney care and hypertension solutions. He ... over 20 years of career experience, as well as ...
(Date:9/6/2017)... Sept. 6, 2017   PDI , a leader in ... host an educational session focused on the role of ... prevention at the 2017 Annual Scientific Meeting of the ... place at the Phoenix Convention ... Sept. 16-19, will also feature PDI,s Prevantics® Device ...
(Date:9/6/2017)... 2017 Eli Lilly and Company (NYSE: ... data for galcanezumab and lasmiditan, two investigational treatments for ... Society (IHC) taking place Sept. 7-10 in ... new, long-term data from an open-label study evaluating the ... mg and 240 mg) for the prevention of migraine. ...
Breaking Medicine Technology: